Equity Profile

GH

Guardant Health, Inc.

Health CareHealth Care Services$21.4B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on precision oncology, providing blood tests for cancer detection and monitoring....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for signs of improvement.

$-0.30

Revenue

Revenue growth is crucial for assessing the company's market demand and operational efficiency.

$339M

Wall Street expectations, options signals, track record, and call prep available with Pro.

GH Q2-2026 Earnings Preview

Context

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on precision oncology, providing blood tests for cancer detection and monitoring. With a market cap of $21 billion, it plays a significant role in the growing field of cancer diagnostics, which is increasingly important as personalized medicine gains traction.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

In Q1 2026, Guardant Health reported an EPS of $-0.45, which was better than analysts' expectations of $-0.71, marking a significant surprise. The stock reacted positively, gaining 0.01% the following day.

Management Promises & Guidance

Continued focus on expanding their product offerings in cancer diagnostics.
Commitment to improving operational efficiencies to drive revenue growth.
Plans to enhance partnerships with healthcare providers for better market reach.

Expectations

Wall Street Expectations

Analysts expect Guardant Health to report a loss but are hopeful for a smaller deficit compared to previous quarters. Revenue estimates suggest steady demand for their cancer detection products.

Bull Case

If the company can exceed revenue expectations and show a narrower loss, it could signal a turnaround in their financial performance, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet revenue estimates or reports a larger loss, it could raise concerns about its growth prospects and operational challenges.

Key Metrics to Watch

EPS

$-0.30

Earnings per share is a key indicator of profitability, and investors will be looking for signs of improvement.

Revenue

$339M

Revenue growth is crucial for assessing the company's market demand and operational efficiency.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Guardant Health achieve revenue of at least $339 million?

Meeting or exceeding this revenue target will be crucial in demonstrating demand for their products and could positively influence investor sentiment.

Can the company narrow its EPS loss to $-0.30 or better?

A smaller loss than expected could indicate improving operational efficiency and a path toward profitability, which is vital for long-term growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new product launches and partnerships, which could significantly impact performance this quarter.

Supporting Evidence

The company's recent product innovations may not be fully reflected in revenue expectations.

Guardant's strong track record of beating EPS estimates suggests there could be upside potential.

Options pricing indicates a high level of expected volatility, which may reflect underlying bullish sentiment.

Key Risk

If revenue growth exceeds $339 million, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether the company can maintain momentum in a competitive market.

Bull Confirmed If

Achieving revenue growth of at least $339 million with an EPS loss of $-0.30 or better would confirm the bull case.

Bear Confirmed If

Reporting revenue below $332 million or an EPS loss greater than $-0.36 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.22%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±28.2% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.6%

Calls (119K)P/C Ratio: 0.19Puts (15K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant Health beats expectations, history suggests the stock could rise around 1.55% on the following day, confirming a positive outlook.

In-Line / Cautious

If results come in as expected, the market may react cautiously, leading to minimal movement as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline, with past misses leading to an average drop of around 4.64%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on partnerships with healthcare providers and their effectiveness.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue expectations and market conditions.
5Discussion on competitive landscape and how Guardant plans to differentiate itself.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Guardant Health, Inc. is a healthcare company focused on precision oncology, providing blood tests for cancer detection and monitoring....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for signs of improvement.

$-0.30

Revenue

Revenue growth is crucial for assessing the company's market demand and operational efficiency.

$339M

Wall Street expectations, options signals, track record, and call prep available with Pro.

GH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+38.36%

Avg Stock Reaction

+1.55%

Last Quarter Recap

Management Promises & Guidance

Continued focus on expanding their product offerings in cancer diagnostics.
Commitment to improving operational efficiencies to drive revenue growth.
Plans to enhance partnerships with healthcare providers for better market reach.

Expectations

Wall Street Expectations

Analysts expect Guardant Health to report a loss but are hopeful for a smaller deficit compared to previous quarters. Revenue estimates suggest steady demand for their cancer detection products.

Bull Case

If the company can exceed revenue expectations and show a narrower loss, it could signal a turnaround in their financial performance, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet revenue estimates or reports a larger loss, it could raise concerns about its growth prospects and operational challenges.

Key Metrics to Watch

EPS

$-0.30

Earnings per share is a key indicator of profitability, and investors will be looking for signs of improvement.

Revenue

$339M

Revenue growth is crucial for assessing the company's market demand and operational efficiency.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Guardant Health achieve revenue of at least $339 million?

Meeting or exceeding this revenue target will be crucial in demonstrating demand for their products and could positively influence investor sentiment.

Can the company narrow its EPS loss to $-0.30 or better?

A smaller loss than expected could indicate improving operational efficiency and a path toward profitability, which is vital for long-term growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new product launches and partnerships, which could significantly impact performance this quarter.

Supporting Evidence

The company's recent product innovations may not be fully reflected in revenue expectations.

Guardant's strong track record of beating EPS estimates suggests there could be upside potential.

Options pricing indicates a high level of expected volatility, which may reflect underlying bullish sentiment.

Key Risk

If revenue growth exceeds $339 million, it could challenge the current bearish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will indicate whether the company can maintain momentum in a competitive market.

Bull Confirmed If

Achieving revenue growth of at least $339 million with an EPS loss of $-0.30 or better would confirm the bull case.

Bear Confirmed If

Reporting revenue below $332 million or an EPS loss greater than $-0.36 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.22%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±28.2% while GH has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.6%

Calls (119K)P/C Ratio: 0.19Puts (15K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Guardant Health beats expectations, history suggests the stock could rise around 1.55% on the following day, confirming a positive outlook.

In-Line / Cautious

If results come in as expected, the market may react cautiously, leading to minimal movement as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline, with past misses leading to an average drop of around 4.64%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new product launches and their expected impact on revenue.
2Any commentary on partnerships with healthcare providers and their effectiveness.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue expectations and market conditions.
5Discussion on competitive landscape and how Guardant plans to differentiate itself.